Physicians' Academy for Cardiovascular Education

CV risk reduction beyond statin therapy: Exploring the role of icosapent ethyl

In this series of videos, three lipids experts discuss the following topics: residual CV risk, findings of CV outcome trials with icosapent ethyl and potential mechanism of benefit with icosapent ethyl.

Slides: Potential mechanisms of benefit of icosapent ethyl

Slides (presentation) - May 17, 2022 - Online series on CV risk reduction beyond statin therapy
This lecture by prof. Chris Packard, PhD is part of an educational series entitled

This lecture by prof. Chris Packard, PhD is part of an educational series entitled "CV risk reduction beyond statin therapy: Exploring the role of Icosapent ethyl".

Slides: Residual CV risk in patients on statin therapy

Slides (presentation) - May 17, 2022 - Online series on CV risk reduction beyond statin therapy
This lecture by prof. Alberto Zambon, MD, PhD is part of an educational series entitled

This lecture by prof. Alberto Zambon, MD, PhD is part of an educational series entitled "CV risk reduction beyond statin therapy: Exploring the role of Icosapent ethyl".

Slides: Exploring the role of icosapent ethyl based on current clinical evidence

Slides (presentation) - May 17, 2022 - Online series on CV risk reduction beyond statin therapy
This lecture by prof. Wouter Jukema, MD, PhD is part of an educational series entitled

This lecture by prof. Wouter Jukema, MD, PhD is part of an educational series entitled "CV risk reduction beyond statin therapy: Exploring the role of Icosapent ethyl".

Potential mechanisms of benefit of icosapent ethyl

10' education - May 3, 2022 - Prof. Chris Packard, PhD
Prof. Packard shares some thoughts on the potential mechanisms of benefit of icosapent ethyl as seen in the REDUCE-IT trial.

Prof. Packard shares some thoughts on the potential mechanisms of benefit of icosapent ethyl as seen in the REDUCE-IT trial.

Discussion - CV risk reduction beyond statin therapy: Exploring the role of Icosapent ethyl

10' education - Apr. 21, 2022 - Prof. Ulrich Laufs, MD, PhD, prof. Chris Packard, PhD and prof. Wouter Jukema, MD, PhD
Watch a discussion by three experts on potential mechanisms, side effects, patient selection, parameters for monitoring and future studies with regard to icosapent ethyl.

Watch a discussion by three experts on potential mechanisms, side effects, patient selection, parameters for monitoring and future studies with regard to icosapent ethyl.

Exploring the role of icosapent ethyl based on current clinical evidence

10' education - Apr. 21, 2022 - Prof. Wouter Jukema, MD, PhD
What are key findings of two CV outcomes trials with icosapent ethyl? Prof. Jukema provides an overview and discusses remaining questions with regard to findings of REDUCE-IT.

What are key findings of two CV outcomes trials with icosapent ethyl? Prof. Jukema provides an overview and discusses remaining questions with regard to findings of REDUCE-IT. With poll.

Residual CV risk in patients on statin therapy

10' education - Apr. 13, 2022 - Prof. Alberto Zambon, MD, PhD
Prof. Zambon talks about established and emerging risk factors that may contribute to residual CV risk in  patients who are already being treated with statins.

Prof. Zambon talks about established and emerging risk factors that may contribute to residual CV risk in patients who are already being treated with statins.

CV risk reduction beyond statin therapy: Exploring the role of icosapent ethyl